JP2019527044A - 抗菌ペプチド誘導体及びその使用 - Google Patents
抗菌ペプチド誘導体及びその使用 Download PDFInfo
- Publication number
- JP2019527044A JP2019527044A JP2018567676A JP2018567676A JP2019527044A JP 2019527044 A JP2019527044 A JP 2019527044A JP 2018567676 A JP2018567676 A JP 2018567676A JP 2018567676 A JP2018567676 A JP 2018567676A JP 2019527044 A JP2019527044 A JP 2019527044A
- Authority
- JP
- Japan
- Prior art keywords
- antimicrobial peptide
- hydrophobic
- micelle
- nucleic acid
- hydrophobically modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 78
- 108700042778 Antimicrobial Peptides Proteins 0.000 title claims abstract description 73
- 102000044503 Antimicrobial Peptides Human genes 0.000 title claims abstract description 73
- 239000000693 micelle Substances 0.000 claims abstract description 84
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 52
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 32
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 32
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 32
- 239000002671 adjuvant Substances 0.000 claims abstract description 29
- 239000012634 fragment Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 11
- 230000004048 modification Effects 0.000 claims abstract description 10
- 238000012986 modification Methods 0.000 claims abstract description 10
- 239000004599 antimicrobial Substances 0.000 claims abstract description 8
- 108020004459 Small interfering RNA Proteins 0.000 claims description 69
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 33
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims description 31
- 230000000844 anti-bacterial effect Effects 0.000 claims description 30
- -1 sterol compound Chemical class 0.000 claims description 24
- 235000012000 cholesterol Nutrition 0.000 claims description 18
- 239000003242 anti bacterial agent Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 13
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 12
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 12
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 12
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 11
- 230000003115 biocidal effect Effects 0.000 claims description 10
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 9
- 239000004380 Cholic acid Substances 0.000 claims description 9
- 235000019416 cholic acid Nutrition 0.000 claims description 9
- 229960002471 cholic acid Drugs 0.000 claims description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 7
- 235000021355 Stearic acid Nutrition 0.000 claims description 7
- 229930182558 Sterol Natural products 0.000 claims description 7
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- 239000008117 stearic acid Substances 0.000 claims description 7
- 235000003702 sterols Nutrition 0.000 claims description 7
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- 239000005639 Lauric acid Substances 0.000 claims description 6
- 235000021314 Palmitic acid Nutrition 0.000 claims description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 6
- 108010059993 Vancomycin Proteins 0.000 claims description 6
- 229940124350 antibacterial drug Drugs 0.000 claims description 6
- 229960003276 erythromycin Drugs 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 229960003165 vancomycin Drugs 0.000 claims description 6
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 6
- 238000007112 amidation reaction Methods 0.000 claims description 5
- 150000001413 amino acids Chemical group 0.000 claims description 5
- 230000000845 anti-microbial effect Effects 0.000 claims description 5
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 229960004821 amikacin Drugs 0.000 claims description 4
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 4
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims description 4
- 229960004099 azithromycin Drugs 0.000 claims description 4
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 4
- 229960000707 tobramycin Drugs 0.000 claims description 4
- 229930186147 Cephalosporin Natural products 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 229930182555 Penicillin Natural products 0.000 claims description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 3
- 230000009435 amidation Effects 0.000 claims description 3
- 229940126574 aminoglycoside antibiotic Drugs 0.000 claims description 3
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims description 3
- 229940124587 cephalosporin Drugs 0.000 claims description 3
- 150000001780 cephalosporins Chemical class 0.000 claims description 3
- 230000009368 gene silencing by RNA Effects 0.000 claims description 3
- 238000010362 genome editing Methods 0.000 claims description 3
- 230000001571 immunoadjuvant effect Effects 0.000 claims description 3
- 239000000568 immunological adjuvant Substances 0.000 claims description 3
- 229940049954 penicillin Drugs 0.000 claims description 3
- 239000002132 β-lactam antibiotic Substances 0.000 claims description 3
- 229940124586 β-lactam antibiotics Drugs 0.000 claims description 3
- JETQIUPBHQNHNZ-NJBDSQKTSA-N (2s,5r,6r)-3,3-dimethyl-7-oxo-6-[[(2r)-2-phenyl-2-sulfoacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound C1([C@H](C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)S(O)(=O)=O)=CC=CC=C1 JETQIUPBHQNHNZ-NJBDSQKTSA-N 0.000 claims description 2
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 2
- 241000222122 Candida albicans Species 0.000 claims description 2
- 241000222173 Candida parapsilosis Species 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 claims description 2
- 229930193140 Neomycin Natural products 0.000 claims description 2
- NUAQIRUAZSJTAI-YRPZDAAMSA-N O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@H](N)CC(C)C)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@H](N)CC(C)C)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 NUAQIRUAZSJTAI-YRPZDAAMSA-N 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 229930195708 Penicillin V Natural products 0.000 claims description 2
- 108010093965 Polymyxin B Proteins 0.000 claims description 2
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 claims description 2
- 108010053950 Teicoplanin Proteins 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 108700029371 albomycin Proteins 0.000 claims description 2
- 229960003022 amoxicillin Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 2
- 229960000723 ampicillin Drugs 0.000 claims description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 229940095731 candida albicans Drugs 0.000 claims description 2
- 229940055022 candida parapsilosis Drugs 0.000 claims description 2
- 229960003669 carbenicillin Drugs 0.000 claims description 2
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 claims description 2
- 229960005361 cefaclor Drugs 0.000 claims description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims description 2
- 229960003012 cefamandole Drugs 0.000 claims description 2
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 claims description 2
- 229960001139 cefazolin Drugs 0.000 claims description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims description 2
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 claims description 2
- 229960003719 cefdinir Drugs 0.000 claims description 2
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims description 2
- 229960002100 cefepime Drugs 0.000 claims description 2
- 229960002129 cefixime Drugs 0.000 claims description 2
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 claims description 2
- 229960004261 cefotaxime Drugs 0.000 claims description 2
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims description 2
- 229960002588 cefradine Drugs 0.000 claims description 2
- 229960004755 ceftriaxone Drugs 0.000 claims description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 2
- 229960001668 cefuroxime Drugs 0.000 claims description 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims description 2
- 229940106164 cephalexin Drugs 0.000 claims description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 2
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 claims description 2
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 claims description 2
- 229940107161 cholesterol Drugs 0.000 claims description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims description 2
- 229960004273 floxacillin Drugs 0.000 claims description 2
- 229960002518 gentamicin Drugs 0.000 claims description 2
- 229960004144 josamycin Drugs 0.000 claims description 2
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 claims description 2
- 229960000318 kanamycin Drugs 0.000 claims description 2
- 229930027917 kanamycin Natural products 0.000 claims description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 2
- 229930182823 kanamycin A Natural products 0.000 claims description 2
- 229960002757 midecamycin Drugs 0.000 claims description 2
- 229960004927 neomycin Drugs 0.000 claims description 2
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims description 2
- 108700014375 norvancomycin Proteins 0.000 claims description 2
- 230000009965 odorless effect Effects 0.000 claims description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 claims description 2
- 229960001019 oxacillin Drugs 0.000 claims description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940056360 penicillin g Drugs 0.000 claims description 2
- 229940056367 penicillin v Drugs 0.000 claims description 2
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 claims description 2
- 229960002292 piperacillin Drugs 0.000 claims description 2
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims description 2
- 229960003342 pivampicillin Drugs 0.000 claims description 2
- ZEMIJUDPLILVNQ-ZXFNITATSA-N pivampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 ZEMIJUDPLILVNQ-ZXFNITATSA-N 0.000 claims description 2
- 229920000024 polymyxin B Polymers 0.000 claims description 2
- 229960005266 polymyxin b Drugs 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 claims description 2
- 229940126586 small molecule drug Drugs 0.000 claims description 2
- ZPCCSZFPOXBNDL-RSMXASMKSA-N spiramycin II Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@H](C)O1 ZPCCSZFPOXBNDL-RSMXASMKSA-N 0.000 claims description 2
- 229950006796 spiramycin ii Drugs 0.000 claims description 2
- 229960005322 streptomycin Drugs 0.000 claims description 2
- 229960004932 sulbenicillin Drugs 0.000 claims description 2
- 229960001608 teicoplanin Drugs 0.000 claims description 2
- 229960004659 ticarcillin Drugs 0.000 claims description 2
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 2
- 239000003429 antifungal agent Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 17
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 15
- 229920001184 polypeptide Polymers 0.000 abstract description 9
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 abstract description 5
- 239000007790 solid phase Substances 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 description 70
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 57
- 241000699670 Mus sp. Species 0.000 description 54
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 53
- 210000004027 cell Anatomy 0.000 description 52
- 239000011347 resin Substances 0.000 description 49
- 229920005989 resin Polymers 0.000 description 49
- 206010028980 Neoplasm Diseases 0.000 description 45
- 239000000243 solution Substances 0.000 description 43
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 27
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000000427 antigen Substances 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 210000004443 dendritic cell Anatomy 0.000 description 17
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
- 210000003743 erythrocyte Anatomy 0.000 description 15
- 230000004614 tumor growth Effects 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 14
- 238000001890 transfection Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 230000000638 stimulation Effects 0.000 description 12
- 210000000683 abdominal cavity Anatomy 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 206010003445 Ascites Diseases 0.000 description 10
- 241000252212 Danio rerio Species 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 206010018910 Haemolysis Diseases 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 230000008588 hemolysis Effects 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 108010078791 Carrier Proteins Proteins 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 8
- 230000002519 immonomodulatory effect Effects 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 7
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 7
- 239000012097 Lipofectamine 2000 Substances 0.000 description 7
- 238000009835 boiling Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000562 conjugate Substances 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 210000005084 renal tissue Anatomy 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 230000015788 innate immune response Effects 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 239000008176 lyophilized powder Substances 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000002390 rotary evaporation Methods 0.000 description 5
- 238000001338 self-assembly Methods 0.000 description 5
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 108020005004 Guide RNA Proteins 0.000 description 4
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 4
- 230000002924 anti-infective effect Effects 0.000 description 4
- 238000002189 fluorescence spectrum Methods 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 208000021039 metastatic melanoma Diseases 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 3
- 206010056519 Abdominal infection Diseases 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000005809 anti-tumor immunity Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 2
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 2
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 2
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- YYVIFBVXJYYHCW-UHFFFAOYSA-N Malvin Natural products COc1cc(cc(OC)c1O)C2=C(Cc3c(OC4OC(CO)C(O)C(O)C4O)cc(O)cc3O2)OC5OC(CO)C(O)C(O)C5O YYVIFBVXJYYHCW-UHFFFAOYSA-N 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000001190 Q-PCR Methods 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000011748 cell maturation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004041 dendritic cell maturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000002074 inflammatory monocyte Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- CILLXFBAACIQNS-BTXJZROQSA-O malvin Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 CILLXFBAACIQNS-BTXJZROQSA-O 0.000 description 2
- 229940117886 malvin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000010445 mica Substances 0.000 description 2
- 229910052618 mica group Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 1
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 1
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 1
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6r,7r)-7-[[(2r)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 206010055114 Colon cancer metastatic Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000089 atomic force micrograph Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000011960 computer-aided design Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- 238000007709 nanocrystallization Methods 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000006807 siRNA silencing Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001135—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
であり、式中、Rはコレステロール化合物、コール酸、又は長鎖脂肪酸である。
である。
a ポリペプチドVQWRIRVAVIRK−NH2を提供する工程と、
b ポリペプチドVQWRIRVAVIRK−NH2の窒素末端に疎水性フラグメントを結合させる工程と
を含む。
a.請求項1〜9のいずれか1項に記載の疎水性修飾抗菌ペプチドの適切な量を秤量し、溶解するための溶液を添加し、自発的にミセルを形成する工程、又は溶液を形成するために請求項9〜12のいずれか1項に記載のミセルを取る工程と、
b.ミセル溶液に核酸を添加し、室温でインキュベートする工程と、
を含む。
(1)バンコマイシン(VAN)
である。
(1)黄色ブドウ球菌(Staphylococcus aureus):ATCC 33591、ATCC 25923、
(2)大腸菌(Escherichia colibacillus):ATCC 25922、
(3)緑膿菌(Pseudomonas aeruginosa):ATCC 10145、ATCC 10145GFP
である。
2.粒径とゼータ電位の検出:DP7−CをMilliq水に溶解し、Malvin粒度計で粒径とゼータ電位を測定し、各試料を4回検出して平均値を得た。
3.DP7−Cの外観と溶液状態:MilliQ水、DP7−C水溶液、及び凍結乾燥粉末の外観を観察し、カメラで写真を撮影した。ここで、aはMilliQ水、bは水溶液に溶解したDP7−C、Cは再溶解後のDP7−C凍結乾燥粉末の状態、dはDP7−C凍結乾燥粉末の形状及び色である。
2.抗凝固剤を取り出し、等尺性生理食塩水を加え、ゆっくりと均一に混ぜ合わせ、400×gで10分間遠心し、上清を捨てた。
3.赤血球をゆっくり混合してPBSで洗浄し、400×gで10分間遠心し、上清を捨て、細胞沈殿物をPBSで3回洗浄した。
4.PBSで希釈して20%(v/v)の赤血球溶液を得、これはすぐに使用するか、又は4℃で約2週間保存することができる(溶血なし)。
5.薬物をPBSで一連の濃度勾配に希釈し、100μLの薬物を96ウェルプレートに加え、100μLの2%Twain 20を陽性対照として取り、100μLのPBSを陰性対照に加えた。この過程を各濃度の薬物について3回繰り返した。
6.20:1の体積比に従って20%(v/v)の赤血球溶液をPBSで希釈し、均一に混合し、それぞれ100、200、400、600、800、1000、1200、1600μg/mLの薬物濃度で96ウェルプレートに加え、37℃で1時間インキュベートした。
7.薬物と赤血球の混合液をインキュベートし、900×gで10分間遠心し、160μLの上清を新しい96ウェルプレートに加え、OD450nmの吸光度の値を読んだ。
8.A450の吸光度の値に基づいて、薬物の各濃度に対応する溶血の割合を計算した。
である。
NS群:マウス1匹あたり通常生理食塩水100μL、
DP7−C群:0.3mg/kg、
VAN陽性対照群:10mg/kg
とした。
(1)実験前日に黄色ブドウ球菌33591をMHBで活性化し、実験当日に活性化株を通常生理食塩水で2回洗浄し、後で使用するために細菌液の濃度を測定した。
(2)腹部感染マウスモデルを確立するために、1.5×108cfu/0.5mLの細菌溶液を各マウスに腹腔内注射した。
(3)1時間の感染後、群ごとに0.1mL/マウスで薬物を静脈内注射した。
(4)24時間後、5mLの通常生理食塩水をマウスに腹腔内注射し、腹部を軽くマッサージし、マウスを屠殺し、75%アルコールで消毒した。5分後、腹腔上皮をはさみで切り、腹腔に小さな開口部を作り、1mlの注射器で開口部からできるだけ多くの腹水を引き、次に、混合するために滅菌EPチューブに移した。
(5)通常生理食塩水で例えば10倍、100倍、1000倍、及び10000倍の希釈度で希釈し、各々20μLの適切な濃度の3つの細菌性溶液を取り、MHAプレートにコーティングし、バクテリアインキュベーターで一晩インキュベートした。
(6)20〜200コロニーを有するプレートを選択し、腹水5mL中のmLあたりの細菌の量を変換し計算した。
分類:マウスを各群5匹の2群(NS群及びDP7−C群)に無作為に分ける。検出された免疫細胞及びそれらの表面マーカーを以下の表に示す。
DP7−C刺激後のマウスPBMC中のサイトカインの変化を決定するために、単離したマウスPBMCを1×106細胞/mLに希釈し、6ウェルプレートに2ml/ウェルで加え、DP7−Cの刺激濃度は200μg/ml、刺激時間は4時間とした。刺激後、細胞を集めて−80℃の冷蔵庫に保存した。一方、DP7−CがLPS誘発炎症反応を逆転させることができるかどうかを検証するために、LPSと共にPBMCを刺激するように実験を設定した。PBMCを1×106細胞/mlに希釈し、6ウェルプレートに2mL/ウェルで加え、DP7−Cの刺激濃度を200μg/mLとし、1時間後、LPSで4時間刺激し、細胞を集め、−80℃の冷蔵庫に保存した。全てのサンプルを収集した後、遠心分離、洗浄、全RNA抽出、逆転写、及びリアルタイム定量的PCRを含むその後の工程を行った。
C57BL/6J雌性マウスを、各群10匹の4群に無作為に分け、
NS群:通常生理食塩水100μL、
CpG群:10μgのOVA+20μgのCpG、
DP7−C群:10μgのOVA+40μgのDP7−C、
CpG/DP7−C群:10μgのOVA+40μgのDP7−C+20μgのCpG
とした。
樹状細胞(DC)の成熟は、免疫応答又は身体の耐性を主に決定する。それらの表面抗原CD80、CD86、及びMHC−IIは明らかに、DCの成熟と共に上方制御されている。従って、本発明者らは、フローサイトメトリーによって樹状細胞成熟に対するDP7−Cアジュバントの効果を検出した。
(1)C57/BLマウス初代骨髄細胞を単離し、10ng/mlのGM−CSF及び10ng/mlのIL−4を含有する誘導培地中で5日間インキュベートした。
(2)DP7−CアジュバントをDC細胞培養液に添加し、よく混合して16時間インキュベートした。
(3)刺激したDC細胞を集め、PBSで2回洗浄し、100μLのPBSに細胞を再懸濁し、1μLの抗マウスCD16/CD32を加え、4℃で30分間ブロッキングした。
(4)PBSで3回洗浄し、1μgのFITC−抗CD80、APC−抗CD86、及びPE−抗MHC−IIを加え、室温で30分間インキュベートし、PBSを3回洗浄し、フローサイトメトリーのために200μLのPBSに再懸濁した。
DC細胞は体内で最も強力な抗原提示細胞であり、異物を吸収し、それらを処理し、T細胞に提示して免疫応答を刺激することができる。DC細胞は、T細胞免疫応答及びT細胞依存性抗体の産生において重要な役割を果たす。本発明者らは、フローサイトメトリーによって、DC提示抗原に対するDP7−Cの効果を調べた。
(1)C57/BLマウス初代骨髄細胞を単離し、10ng/mlのGM−CSF及び10ng/mlのIL−4を含有する誘導培地中で5日間インキュベートした。
(2)DC細胞培養液にOVAタンパク質マーカーFITC、OVA、又はDP7−C/OVAを添加し、よく混合し、3時間インキュベートした。
(3)刺激したDC細胞を回収し、PBSで2回洗浄し、300μLのPBSに細胞を再懸濁し、フローサイトメトリーを行った。
一次免疫の48時間後、頸椎脱臼によってマウスを屠殺し、エフェクター細胞としてリンパ球分離培地から脾臓リンパ球を単離した。
YAC−1細胞を蘇生し、インキュベートし、実験の前日に移し、2×106/20mlを保った。トリパンブルーで染色した。活性が95%以上の場合に利用可能である。
1.96ウェルプレートに標的細胞とエフェクター細胞を加え(標的細胞対エフェクター細胞の比率は、1ウェルあたり10,000個の標的細胞について1:25、1:50、1:100、1:200)、37℃で4時間インキュベートした。
2.250gで遠心し、上清を取り出してLDH放出試験を行った。
1.7日間で3回免疫した後、マウスの脾臓リンパ球を分離し、計数し、5×106/mlまで希釈した。
2.6ウェルプレートに5×106/ウェルで入れ、各ウェルに10μg/mlのOVAホロタンパク質を加え、37℃で1時間刺激した(陰性対照:DMSO、陽性対照:5μg/ml conA)。
3.各ウェルに1μLのゴルジプラグを加えてよく混ぜ、6〜12時間インキュベートした。
1.細胞を集めて2mlの1×BD Pharmlyseボルテックスに加え、暗所にて室温で10分間インキュベートし、500gで5分間遠心し、上清を捨てた。
2.1×instaining bufferで洗浄後、100μLの1×instaining bufferに再懸濁し、1μLの抗マウスCD16/CD32を加え、4℃で15分間インキュベートしてブロッキングした。
3.1×instaining bufferで洗浄後、100μlの染色バッファーに再懸濁し、PE抗マウスCD8とperCP−cy5抗マウスCD4をそれぞれ1μl加え、暗所にて4℃で30分間インキュベートした。
4.染色バッファーで2回洗浄した後、250μlの固定化/透過化ボルテックスを加えて完全に懸濁させ、暗所にて室温で20分間インキュベートし、細胞を固定化し透過化した。
(7)2mLのBD Perm/洗浄バッファーを加え、500gで5分間遠心し、上清を捨てた。
(8)100μLのBD Perm/洗浄バッファーに細胞を再懸濁し、細胞内抗原抗体(FITC−IFN−γ又はPE−IL−17A)を添加し、暗所にて室温で30分間インキュベートした。その後、2mlのBD Perm/洗浄バッファーを加え、500gで5分間遠心し、上清を捨てた。2%パラホルムアルデヒドを含む500μlのPBSに再懸濁した。ボルテックスが完全に停止したら、フローサイトメトリーを実行することができる。
具体的な手順は次の通りである。
20μgのCpGと40μgのDP7−Cを37℃で15分間インキュベートし、5μgのNY−ESO−1タンパク質を加え、滅菌PBSを用いて100μlの容量になるまで補充した。
本研究では、動物実験は、各群10匹のマウスをNS、CpG、DP7−C、及びCpG/DP7−Cの5群に分け、各マウスの投与量は、
1.NS群:PBS100μl、
2.CpG群:NY−ESO−1タンパク質5μg+CpG20μg、
3.DP7−C群:NY−ESO−1タンパク質5μg+DP7−C40μg、
4.CpG/DP7−C群:NY−ESO−1タンパク質5μg+CpG20μg+DP7−C40μg
とした。
(2)3日目に、マウスを各群8匹ずつ4群に無作為に分け、標識した。
(3)4群のマウスにそれぞれ、10用量の通常生理食塩水(ブランク対照群)、ブランクDP7−Cミセル(17.5μg)、DP7−C/無センス対照siRNA(スクランブルsiRNA)複合体(17.5μg/3.5μg)、又はDP7−C/VEGF siRNA複合体(17.5μg/3.5μg)を腹腔内注射した。
(4)20日目に、対照群のマウスが既に非常に弱っているときに、全てのマウスを頸椎脱臼により屠殺し、腹腔内の腫瘍組織、並びに心臓、肝臓、脾臓、肺、及び腎臓の組織を直ちに採取し、秤量し、分析した。また、各群のマウスの腹水も収集及び測定し、CD31免疫組織化学的染色を各実験群の腫瘍組織に対して行った。採取した心臓、肝臓、脾臓、肺、及び腎臓の組織をHE染色で分析した。
(1)0日目に、6〜8週齢の雌性BALB/cマウスに0.1mLの細胞懸濁液(約1.5×106個のC26細胞を含む)を皮下接種した。
(2)8日目に、腫瘍が触診可能になったとき、マウスを各群8匹ずつ4群に無作為に分け、標識した。
(3)4群のマウスにそれぞれ、10用量の通常生理食塩水(ブランク対照群)、ブランクDP7−Cミセル(25μg)、DP7−C/無センス対照siRNA複合体(25μg/5μg)、又はDP7−C/VEGF siRNA複合体(25μg/5μg)を腫瘍内注射した。
(4)20日目に、対照群のマウスが既に非常に弱っているときに、全てのマウスを頸椎脱臼により屠殺し、腹腔内の腫瘍組織、並びに心臓、肝臓、脾臓、肺、及び腎臓の組織を直ちに採取し、秤量し、分析した。また、各群のマウスの腹水も収集及び測定し、CD31免疫組織化学的染色を各実験群の腫瘍組織に対して行った。採取した心臓、肝臓、脾臓、肺、及び腎臓の組織をHE染色で分析した。
(1)0日目に、6〜8週齢の雌性C57マウスに0.1mLの細胞懸濁液(約2.5×105個のB16細胞を含む)を皮下接種した。
(2)3日目に、マウスを各群8匹ずつ4群に無作為に分け、標識した。
(3)7用量の通常生理食塩水(ブランク対照群)、ブランクDP7−Cミセル(60μg)、DP7−C /無センス対照siRNA複合体(60μg/12μg)、又はDP7−C/VEGF siRNA複合体(60μg/12μg)を、それぞれ尾静脈を通じてマウスに注射した。
(4)20日目に、対照群のマウスが既に非常に弱っているときに、全てのマウスを頸椎脱臼により屠殺し、肺、並びに心臓、肝臓、脾臓、肺、及び腎臓の組織中の腫瘍組織を直ちに採取し、秤量し、分析した。採取した心臓、肝臓、脾臓、肺、及び腎臓の組織をHE染色で分析した。
Claims (38)
- 疎水性修飾が、抗菌ペプチドの窒素末端に疎水性フラグメントを結合させることであり、前記抗菌ペプチドのアミノ酸配列がVQWRIRVAVIRKである、疎水性修飾抗菌ペプチド。
- 前記抗菌ペプチドVQWRIRVAVIRKが、C末端アミド化によって修飾されてVQWRIRVAVIRK−NH2を生成する、請求項1に記載の疎水性修飾抗菌ペプチド。
- 前記疎水性フラグメントがステロール化合物又は飽和直鎖脂肪酸である、請求項1又は2に記載の疎水性修飾抗菌ペプチド。
- 前記ステロール化合物がコレステロール化合物またはコール酸化合物である、請求項1〜3のいずれか1項に記載の疎水性修飾抗菌ペプチド。
- 前記ステロール化合物が、スクシニル化コレステロール、コール酸、又はデオキシコール酸のうちの少なくとも1つである、請求項3に記載の疎水性修飾抗菌ペプチド。
- 前記飽和直鎖脂肪酸が炭素数6〜20の少なくとも1つである、請求項3に記載の疎水性修飾抗菌ペプチド。
- 前記飽和直鎖脂肪酸が炭素数8〜18の少なくとも1つである、請求項6に記載の疎水性修飾抗菌ペプチド。
- 長鎖脂肪酸が、ステアリン酸、パルミチン酸、ラウリン酸、又はn−オクタン酸の少なくとも1つである、請求項7に記載の疎水性修飾抗菌ペプチド。
- 前記抗菌ペプチドの前記窒素末端が、疎水性セグメントの−CO−OHと抗菌ペプチドの−NH2とのアミド化反応によって疎水性セグメントに結合されている、請求項1〜8のいずれか1項に記載の疎水性修飾抗菌ペプチド。
- 前記疎水性修飾抗菌ペプチドの構造が、
であり、
式中、Rはステロール化合物又は飽和直鎖脂肪酸である、請求項1〜9のいずれか1項に記載の疎水性修飾抗菌ペプチド。 - Rが、
である、請求項10に記載の疎水性修飾抗菌ペプチド。 - 請求項1〜11のいずれか1項に記載の疎水性修飾抗菌ペプチドから調製されたミセル。
- 前記ミセルが、溶液中で前記疎水性修飾抗菌ペプチドから自己集合している、請求項12に記載のミセル。
- 前記ミセルが、核酸、小分子薬、又はタンパク質のうちの少なくとも1つを更に搭載している、請求項12又は13に記載のミセル。
- 抗菌薬の調製における、請求項1〜11のいずれか1項に記載の疎水性修飾抗菌ペプチド又は請求項12〜14のいずれか1項に記載のミセルの使用。
- 抗菌剤が抗菌剤又は抗真菌剤である、請求項15に記載の使用。
- 細菌が、黄色ブドウ球菌(Staphylococcus aureus)、大腸菌(Escherichia colibacillus)、アシネトバクター・バウマニ(Acinetobacter baumanmii)、緑膿菌(Pseudomonas aeruginosa)、又はまたはチフス菌(Salmonella typhi)のうちの少なくとも1つである、請求項16に記載の使用。
- 真菌が、カンジダ・アルビカンス(Canidia Albicans)又はカンジダ・パラプシローシス(Candida parapsilosis)のうちの少なくとも1つである、請求項15に記載の使用。
- 抗菌薬が、主たる有効成分、即ち請求項1〜11のいずれか1項に記載の疎水性修飾抗菌ペプチド又は請求項12〜14のいずれか一項に記載のミセルから調製される、抗菌薬。
- 他の抗菌薬を更に含む、請求項19に記載の抗菌薬。
- 前記他の抗菌薬が抗生物質である、請求項20に記載の抗菌薬。
- 前記抗生物質が、グリコペプチド系抗生物質、アミノグリコシド系抗生物質、マクロライド系抗生物質、及びβ−ラクタム系抗生物質のうちの少なくとも1つである、請求項21に記載の抗菌薬。
- ペニシリン系抗生物質が、ペニシリンG、ペニシリンV、フルクロキサシリン、オキサシリン、アンピシリン、カルボキシベンジルペニシリン、ピバンピシリン、スルベニシリン、チカルシリン、ピペラシリン、又はアモキシシリンのうちの少なくとも1つであり、セファロスポリン系抗生物質が、セファドロキシル、セファレキシン、セファゾリン、セフラジン、セフプロジル、セフロキシム、セファクロル、セファマンドール、セフォタキシム、セフトリアキソン、セフィキシム、セフジニル、セフピロム、セフェピム、又はセフゾナムのうちの少なくとも1つである、請求項22に記載の抗菌薬。
- アミノグリコシド系抗生物質が、ストレプトマイシン、ゲンタマイシン、カナマイシン、トブラマイシン、アミカシン、ネオマイシン、シソマイシン、トブラマイシン、アミカシン、ネチルマイシン、リボザイム、ミクロノマイシン、又はアジスロマイシンのうちの少なくとも1つである、請求項22に記載の抗菌薬。
- ポリペプチド抗生物質が、バンコマイシン、ノルバンコマイシン、ポリミキシンB、又はテイコプラニンのうちの少なくとも1つである、請求項22に記載の抗菌薬。
- マクロライド系抗生物質が、エリスロマイシン、アルボマイシン、無臭エリスロマイシン、エリスロマイシンエストレート、アセチルスピラマイシン、ミデカマイシン、ジョサマイシン、又はアジスロマイシンのうちの少なくとも1つである、請求項22に記載の抗菌薬。
- 免疫アジュバントの調製における、請求項1〜11のいずれか1項に記載の疎水性修飾抗菌ペプチド又は請求項12〜14のいずれか1項に記載のミセルの使用。
- 免疫アジュバントが主成分、即ち、請求項1〜11のいずれか1項に記載の疎水性修飾抗菌ペプチド又は請求項12〜14のいずれか1項に記載のミセルから調製される、免疫アジュバント。
- 一本鎖オリゴデオキシリボヌクレオチドCpG ODNを更に含む、請求項28に記載の免疫アジュバント。
- 疎水性修飾抗菌ペプチド対CpG ODNの比が1:0.5〜1:5である、請求項28又は29に記載の免疫アジュバント。
- 核酸トランスポーターの調製における、請求項1〜11のいずれか1項に記載の疎水性修飾抗菌ペプチド又は請求項12〜14のいずれか1項に記載のミセルの使用。
- 前記核酸がRNAである、請求項31に記載の使用。
- 前記核酸が、mRNA、RNA干渉のためのsiRNA、又はゲノム編集のためのsgRNAのうちの少なくとも1つである、請求項32記載の使用。
- 請求項1〜11のいずれか1項に記載の疎水性修飾抗菌ペプチド又は請求項12〜14のいずれか1項に記載のミセルに搭載された核酸によって得られる、核酸トランスポーター。
- 前記核酸がRNAである、請求項34に記載の核酸トランスポーター。
- 前記核酸がmRNA、siRNA、又はsgRNAである、請求項34に記載の核酸トランスポーター。
- 前記疎水性修飾抗菌ペプチド対前記核酸の質量比が、1:1〜20:1である、請求項34〜36のいずれか1項に記載の核酸トランスポーター。
- a.請求項1〜11のいずれか1項に記載の疎水性修飾抗菌ペプチドの適切な量を秤量し、溶解するための溶液を添加し、自発的にミセルを形成する工程;又は溶液を形成するために請求項12〜14のいずれか1項に記載のミセルを取る工程と、
b.ミセル溶液に核酸を添加し、室温でインキュベートする工程と、
を含む、請求項34〜36のいずれか1項に記載の核酸トランスポーターの調製方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021071796A JP7190209B2 (ja) | 2016-07-01 | 2021-04-21 | 抗菌ペプチド誘導体及びその使用 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610517446.0 | 2016-07-01 | ||
CN201610517372 | 2016-07-01 | ||
CN201610517446 | 2016-07-01 | ||
CN201610517372.0 | 2016-07-01 | ||
PCT/CN2017/091390 WO2018001383A1 (zh) | 2016-07-01 | 2017-07-01 | 抗菌肽衍生物及其用途 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021071796A Division JP7190209B2 (ja) | 2016-07-01 | 2021-04-21 | 抗菌ペプチド誘導体及びその使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019527044A true JP2019527044A (ja) | 2019-09-26 |
Family
ID=60487245
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018567676A Pending JP2019527044A (ja) | 2016-07-01 | 2017-07-01 | 抗菌ペプチド誘導体及びその使用 |
JP2021071796A Active JP7190209B2 (ja) | 2016-07-01 | 2021-04-21 | 抗菌ペプチド誘導体及びその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021071796A Active JP7190209B2 (ja) | 2016-07-01 | 2021-04-21 | 抗菌ペプチド誘導体及びその使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190216939A1 (ja) |
EP (1) | EP3480208A4 (ja) |
JP (2) | JP2019527044A (ja) |
CN (4) | CN107441501B (ja) |
WO (1) | WO2018001383A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210124923A (ko) * | 2020-04-07 | 2021-10-15 | (주) 캠프테라퓨틱스 | 신규한 항균 펩타이드 또는 펩타이드 유사체 및 이의 용도 |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108264539B (zh) * | 2017-12-28 | 2020-12-25 | 河南科技学院 | 一种抗菌肽rl-18及其应用 |
CN109966170B (zh) * | 2018-02-13 | 2022-04-15 | 深圳高尚科美生物科技有限公司 | 包含生物大分子的柔性脂质体化妆品及其制备方法 |
CN109998994B (zh) * | 2018-02-13 | 2021-12-07 | 四川大学 | 包含药物的柔性脂质体及其制备方法 |
CN109700671B (zh) * | 2018-02-13 | 2022-04-15 | 深圳高尚科美生物科技有限公司 | 包含活性小分子物质的柔性脂质体化妆品及其制备方法 |
CN109700687B (zh) * | 2018-02-13 | 2022-04-15 | 深圳高尚科美生物科技有限公司 | 包含活性多肽的柔性脂质体化妆品及其制备方法 |
CZ308104B6 (cs) | 2018-03-12 | 2020-01-08 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. | Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití |
CN109022522B (zh) * | 2018-08-31 | 2021-08-17 | 杭州洪晟生物技术股份有限公司 | 一种gfp-2小肽及其制备方法和应用 |
CN109371048A (zh) * | 2018-11-12 | 2019-02-22 | 四川大学 | 一种利用CRISPRCas9技术敲除大肠杆菌中多粘菌素耐药基因mcr-1的方法 |
CN109485713A (zh) * | 2018-12-10 | 2019-03-19 | 倪京满 | 具有强抗菌活性和低毒性的二聚化修饰抗菌肽类似物及其合成和应用 |
CN111000802B (zh) * | 2019-12-27 | 2021-05-14 | 中山大学 | 一种抗菌肽脂质体制剂及其制备方法 |
CN111748018B (zh) * | 2020-05-19 | 2021-12-14 | 东北农业大学 | 一种有自组装潜力的生物相容性抗菌肽及制备方法和应用 |
CN111588865A (zh) * | 2020-05-25 | 2020-08-28 | 河南科技学院 | 一种内包抗生素外联抗菌肽纳米复合物及其制备方法 |
CN113855634A (zh) * | 2020-06-30 | 2021-12-31 | 四川大学 | 多肽修饰的脂质体、mRNA传递系统及树突状细胞疫苗 |
CN114432262A (zh) * | 2020-10-16 | 2022-05-06 | 四川大学华西医院 | 肝脏靶向小核酸药物缓释递送系统及其应用 |
CN114377140B (zh) * | 2020-10-16 | 2023-08-29 | 四川大学华西医院 | 疏水化修饰多肽在制备microRNA相关核酸传递系统中的用途 |
CN112279890B (zh) * | 2020-11-02 | 2022-10-11 | 皖南医学院 | 一种两亲性多肽、制备方法及应用 |
CN112798671B (zh) * | 2020-12-29 | 2023-09-05 | 中国科学院海洋研究所 | 一种温和裂解细胞的裂解剂及其应用 |
CN112691081B (zh) * | 2021-01-18 | 2022-04-22 | 首都医科大学 | 一种基于(s)-2-癸酰氨基-3-(1-萘基)丙酰基-亮氨酰-缬氨酸的紫杉醇胶束 |
CN112778401B (zh) * | 2021-01-25 | 2022-10-18 | 中国农业大学 | 一种辛酸酰化修饰抗菌肽及其应用 |
CN112791191B (zh) * | 2021-02-03 | 2021-10-08 | 河南工业大学 | 一种新型高效抵抗蛋白酶水解抗多药耐药菌的抗菌肽辛酸偶联物及其应用 |
CN115125211A (zh) * | 2021-03-24 | 2022-09-30 | 核工业总医院 | 免疫治疗疗效评价用结肠癌腹膜转移小鼠模型 |
CN114344261A (zh) * | 2021-12-02 | 2022-04-15 | 四川大学 | 胶束、核酸传递系统及鼻黏膜给药系统 |
CN114344315A (zh) * | 2022-01-18 | 2022-04-15 | 中国中医科学院医学实验中心 | 胆酸与氨基糖苷联用在制备抗金黄色葡萄球菌药物中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110223202A1 (en) * | 2007-12-18 | 2011-09-15 | Yi-Yan Yang | Cationic core-shell peptide nonoparticles |
CN103467579A (zh) * | 2013-08-26 | 2013-12-25 | 华南理工大学 | 一类阳离子两亲性自组装纳米抗菌肽及其应用 |
WO2014053624A1 (en) * | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303575B1 (en) * | 1998-05-12 | 2001-10-16 | The Regents Of The University Of California | Indolicidin analogs and methods of using same |
AT410635B (de) * | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
ZA200602754B (en) * | 2003-09-12 | 2007-06-27 | Univ British Columbia | Effectors of innate immunity determination |
WO2005068492A2 (en) * | 2004-01-06 | 2005-07-28 | The United States Of America As Represented By The Secretary Of Health And Human Services, Nih | Peptide inhibitors of retroviral integrase useful for the treatment of retroviral infection |
WO2006050611A1 (en) * | 2004-11-12 | 2006-05-18 | The University Of British Columbia | Antimicrobial peptides |
US7579318B2 (en) * | 2005-12-06 | 2009-08-25 | Centre De La Recherche De La Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
US8242081B2 (en) * | 2005-12-06 | 2012-08-14 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
US8343475B2 (en) | 2006-08-21 | 2013-01-01 | The University Of British Columbia | Small cationic antimicrobial peptides |
WO2008151434A1 (en) * | 2007-06-12 | 2008-12-18 | The University Of British Columbia | Small cationic antimicrobial peptides |
CA2695385A1 (en) * | 2007-07-31 | 2009-02-05 | Atul Bedi | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
EP2108372A1 (en) * | 2008-04-09 | 2009-10-14 | Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften | Novel antimicrobial peptides |
CN101429233B (zh) * | 2008-10-06 | 2011-10-19 | 南开大学 | 聚乙二醇修饰抗菌肽及用途 |
DE102009007381A1 (de) * | 2009-01-29 | 2010-08-05 | Amp-Therapeutics Gmbh & Co. Kg | Antibiotische Peptide |
CN102180951B (zh) * | 2011-05-03 | 2012-09-26 | 中国医学科学院病原生物学研究所 | 胆固醇修饰的抗hiv多肽药物及其用途 |
CN103908668B (zh) * | 2014-04-03 | 2016-06-29 | 浙江大学 | 蝇蛆抗菌肽佐剂及其制备方法和含该佐剂的疫苗制剂及用途 |
CN104036155B (zh) * | 2014-05-30 | 2018-01-05 | 四川大学 | 抗菌肽抗菌活性预测方法及抗菌肽 |
CN105463002B (zh) * | 2014-08-08 | 2020-06-26 | 中国人民解放军军事医学科学院毒物药物研究所 | 多肽类核酸载体、其制备方法及用途 |
-
2017
- 2017-06-30 CN CN201710524923.0A patent/CN107441501B/zh active Active
- 2017-06-30 CN CN202110933100.XA patent/CN113813231B/zh active Active
- 2017-06-30 CN CN201710527268.4A patent/CN107446019B/zh active Active
- 2017-06-30 CN CN202110926820.3A patent/CN113521007B/zh active Active
- 2017-07-01 US US16/313,228 patent/US20190216939A1/en active Pending
- 2017-07-01 WO PCT/CN2017/091390 patent/WO2018001383A1/zh unknown
- 2017-07-01 JP JP2018567676A patent/JP2019527044A/ja active Pending
- 2017-07-01 EP EP17819379.3A patent/EP3480208A4/en active Pending
-
2021
- 2021-04-21 JP JP2021071796A patent/JP7190209B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110223202A1 (en) * | 2007-12-18 | 2011-09-15 | Yi-Yan Yang | Cationic core-shell peptide nonoparticles |
WO2014053624A1 (en) * | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
CN103467579A (zh) * | 2013-08-26 | 2013-12-25 | 华南理工大学 | 一类阳离子两亲性自组装纳米抗菌肽及其应用 |
Non-Patent Citations (1)
Title |
---|
ANTIMICROB. AGENTS CHEMOTHER., vol. 58, no. 9, JPN6020005860, September 2014 (2014-09-01), pages 5342 - 5349, ISSN: 0004412391 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210124923A (ko) * | 2020-04-07 | 2021-10-15 | (주) 캠프테라퓨틱스 | 신규한 항균 펩타이드 또는 펩타이드 유사체 및 이의 용도 |
KR102381481B1 (ko) | 2020-04-07 | 2022-04-01 | (주) 캠프테라퓨틱스 | 신규한 항균 펩타이드 또는 펩타이드 유사체 및 이의 용도 |
Also Published As
Publication number | Publication date |
---|---|
CN107446019A (zh) | 2017-12-08 |
US20190216939A1 (en) | 2019-07-18 |
WO2018001383A1 (zh) | 2018-01-04 |
CN107446019B (zh) | 2021-10-15 |
CN107441501A (zh) | 2017-12-08 |
EP3480208A4 (en) | 2019-12-18 |
CN107441501B (zh) | 2020-11-10 |
EP3480208A1 (en) | 2019-05-08 |
JP2021121189A (ja) | 2021-08-26 |
CN113813231A (zh) | 2021-12-21 |
CN113521007B (zh) | 2022-11-18 |
CN113521007A (zh) | 2021-10-22 |
CN113813231B (zh) | 2022-06-21 |
JP7190209B2 (ja) | 2022-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7190209B2 (ja) | 抗菌ペプチド誘導体及びその使用 | |
JP6993240B2 (ja) | 結腸直腸癌を治療するための細胞透過性ペプチド、カーゴ、及びtlrペプチドアゴニストを含む新規複合体 | |
ES2298353T3 (es) | Peptido wt1 modificado. | |
Diwan et al. | Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses | |
EP2271661B3 (en) | Derivatives of muramylpeptide | |
Hou et al. | Co-delivery of antigen and dual adjuvants by aluminum hydroxide nanoparticles for enhanced immune responses | |
KR20110039351A (ko) | 이산화 규소 나노입자 및 예방접종을 위한 그의 용도 | |
WO2006112477A1 (ja) | アジュバントとしてのポリアミノ酸 | |
Kitiyodom et al. | The potential of mucoadhesive polymer in enhancing efficacy of direct immersion vaccination against Flavobacterium columnare infection in tilapia | |
KR20190057345A (ko) | 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체 | |
JPWO2005094878A1 (ja) | 抗腫瘍作用を有する組成物 | |
Fang et al. | The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model | |
CN113855634A (zh) | 多肽修饰的脂质体、mRNA传递系统及树突状细胞疫苗 | |
CN104645349A (zh) | 复合型纳米疫苗及其制备方法 | |
CN110613844A (zh) | 一种迷你联合佐剂纳米颗粒及其制备方法和应用 | |
EP3220913A1 (en) | Novel nanoparticle-based vaccine targeting cancer/testis antigens (cta) and its use in solid and hematological malignancies | |
Fujita et al. | Nanoparticle-based peptide vaccines | |
Koirala et al. | Polymeric Nanoparticles as a Self‐Adjuvanting Peptide Vaccine Delivery System: The Role of Shape | |
WO2019086056A1 (es) | Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas | |
CN107050463B (zh) | 一种药物及其制备方法和应用 | |
CN116162138A (zh) | 树枝状多肽及其用途 | |
Zhang et al. | In Situ biomimetic Nanoformulation for metastatic cancer immunotherapy | |
US20190246632A1 (en) | Nucleic acid-peptide capsule complexes | |
CN115025211A (zh) | 用于动脉粥样硬化治疗的纳米疫苗及其制备方法 | |
CN110022894A (zh) | 用于癌症疗法的免疫原性化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190222 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20190829 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190829 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200512 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200715 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200818 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20201222 |